Le Lézard
Classified in: Health, Science and technology, Business
Subjects: EARNINGS, Conference Call, Webcast, Advisory

Mirum Pharmaceuticals to Report Second Quarter 2021 Financial Results and Host Conference Call on August 5, 2021


Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), today announced that the company will report financial results for the quarter ended June 30, 2021 on Thursday, August 5, 2021. That same day, Mirum will host a conference call and audio webcast at 1:30 p.m. PT/4:30 p.m. ET to provide a business update.

Conference Call Details:

U.S. toll-free:

844.200.6205

International:

646.904.5544

Passcode:

097025

You may also access the call via webcast by visiting the Investors & Media section on Mirum's corporate website. A replay of this webcast will be available for 30 days.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. Mirum's lead product candidate, maralixibat, is an investigational oral drug in development for Alagille syndrome (ALGS), progressive familial intrahepatic cholestasis (PFIC), and biliary atresia. Mirum has submitted an NDA for maralixibat in the treatment of cholestatic pruritus in patients with ALGS. The NDA has been accepted for priority review by the FDA with a PDUFA action date of September 29, 2021. Additionally, Mirum's marketing authorization application for the treatment of pediatric patients with PFIC2 has been accepted for review (validated) by the European Medicines Agency. Mirum is also developing volixibat, also an oral ASBT-inhibitor, in primary sclerosing cholangitis, intrahepatic cholestasis of pregnancy, and primary biliary cholangitis. For more information, visit MirumPharma.com.

To augment its pipeline in cholestatic liver disease, Mirum has acquired the exclusive option to develop and commercialize two gene therapy programs, VTX-803 and VTX-802 for PFIC3 and PFIC2, respectively, from Vivet Therapeutics, following preclinical evaluation and IND-enabling studies.

Follow Mirum on Twitter, Facebook, LinkedIn and Instagram.


These press releases may also interest you

at 12:15
FairJourney Biologics S.A., leader in the discovery and optimization of antibodies, today announced, after the overwhelming success of the 2021 ANTIBODY SERIES conference, planning for a larger scale 2022 ANTIBODY SERIES are underway. This year's...

at 12:15
Moderna, Inc. , a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced Health Canada has approved the New Drug Submission (NDS-CV) for SPIKEVAXtm (elasomeran mRNA vaccine), which has been known as COVID-19...

at 12:15
August saw a reversal in the upward momentum the restaurant industry's sales and traffic had been riding in recent months. Amid a rising number of COVID cases and wide media coverage of its Delta variant, sales growth was 6.1% during the month, a...

at 12:11
An unimaginable amount of data is continually being generated by scientific experiments, longitudinal studies, clinical trials, and hospital records?but what can be done with all this information?...

at 12:02
Intermountain Healthcare and SCL Health, two leading nonprofit healthcare organizations, have signed a Letter of Intent to merge and create a model health system that provides high-quality, accessible, and affordable healthcare to more patients and...

at 12:02
GreenLight Biosciences, Inc., a biotechnology company focused on RNA research, design, and manufacturing for human, animal, and plant health, announced the appointment of Jennifer Raymond as SVP, CMC & Manufacturing today. Raymond joins GreenLight...



News published on 29 july 2021 at 16:05 and distributed by: